2026-525568-17-00招募中1 期
Whole body HER2 quantification with 89Zr-Trastuzumab PET/CT to asses Zr-trastuzumab accumulation in HER2-mutated and HER2-overexpressing metastatic non-small cell lung cancer
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年8月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Joop de Langen
Scientific
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
研究点 (1)
Loading locations...
相似试验
撤回
2 期
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer2024-516253-49-00Institut Jules Bordet31
尚未招募
1 期
HER2-Targeting Site-Specific Labelled 89Zr-Trastuzumab PET Imaging of Patients with Cancer2024-516786-37-00Rigshospitalet140
尚未招募
2 期
A study to check whether a lower fixed dose of trastuzumab deruxtecan (T-DXd) works safely and effectively for patients with HER2-low advanced or metastatic breast cancer that has stopped responding to hormone treatment.CTRI/2025/11/097495ICMR32
Enrolling By Invitation
2 期
Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107NCT07292571Tomsk National Research Medical Center of the Russian Academy of Sciences50
招募中
2 期
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT07428044Memorial Sloan Kettering Cancer Center14